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Homeobox NKX2-3 promotes marginal-zone
lymphomagenesis by activating B-cell receptor
signalling and shaping lymphocyte dynamics
Eloy F. Robles1,*, Maria Mena-Varas1,*, Laura Barrio2,w, Sara V. Merino-Cortes2, Pe´ter Balogh3, Ming-Qing Du4,
Takashi Akasaka5, Anton Parker6, Sergio Roa1, Carlos Panizo7, Idoia Martin-Guerrero8, Reiner Siebert8, Victor Segura9,
Xabier Agirre1, Laura Macri-Pellizeri1, Beatriz Aldaz1, Amaia Vilas-Zornoza1, Shaowei Zhang4, Sarah Moody4,
Maria Jose Calasanz10, Thomas Tousseyn11, Cyril Broccardo12, Pierre Brousset12, Elena Campos-Sanchez13,
Cesar Cobaleda13, Isidro Sanchez-Garcia14, Jose Luis Fernandez-Luna15, Ricardo Garcia-Mun˜oz16, Esther Pena17,
Beatriz Bellosillo18, Antonio Salar19, Maria Joao Baptista20, Jesu´s Maria Hernandez-Rivas21, Marcos Gonzalez21,
Maria Jose Terol22, Joan Climent22, Antonio Ferrandez23, Xavier Sagaert11, Ari M. Melnick24, Felipe Prosper1,7,
David G. Oscier6, Yolanda R. Carrasco2, Martin J.S. Dyer5 & Jose A. Martinez-Climent1
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is
overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not
with other B-cell malignancies. While Nkx2-3-deﬁcient mice exhibit the absence of marginal-zone
B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that
leads to the development of tumours, faithfully recapitulating the principal clinical and biological
features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by
phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhe-
sion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules
enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually
driving malignant transformation through triggering NF-kB and PI3K-AKT pathways. This study
implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse
model for studying the biology and therapy of human marginal-zone B-cell lymphomas.
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T
he NKX2 family of orphan homeobox proteins is
composed of transcriptional factors that regulate various
fundamental cellular processes, including head patterning,
cardiac and lung development, and neural cell speciﬁcation1–4.
Several NKX2 members including NKX2-1, NKX2-2 and NKX2-
8 function as oncogenic drivers in solid tumours5–8, whereas
NKX2-1, NKX2-2 and NKX2-5 frequently show genomic
rearrangements leading to deregulated expression in T-cell
acute lymphoblastic leukaemia8–10. The homeobox NKX2-3
protein controls salivary gland, tooth and small intestine
development3,11,12, and has been identiﬁed as an important
regulator of splenic morphology12–14 and vasculature15. In fact,
NKX2-3-deﬁcient mice (Nkx2-3 / ) showed impaired
distribution of B, T and follicular dendritic cells in the spleen
as a consequence of abnormal homing12. However, rather than
modulating intrinsic lymphoid development or speciﬁcation,
NKX2-3 directs the splenic micro-environmental conformation
to allow normal B-cell maturation, and accordingly, bone marrow
reconstitution experiments failed to correct abnormal structures
found in the spleens of Nkx2-3-deﬁcient mice11–13,15–17. In
humans, sequence variants in NKX2-3 gene predispose to Crohn’s
disease and ulcerative colitis development, and NKX2-3
expression is upregulated in tissue samples from these
patients18–20. Beyond these data, little is known about the
functional roles of the homeobox protein NKX2-3, and to date it
has not been implicated in cancer development21.
Chromosomal translocations involving the immunoglobulin
(IG) gene loci are a hallmark of B-cell lymphomas22. Although
the molecular study of the common IG translocations has led to
the discovery of seminal cancer genes such as MYC, BCL2 and
CCND1, cloning of other less frequent translocations has also
identiﬁed genes with critical biological functions, such as BCL9,
BCL10 and BCL11A23. We therefore postulated that the study of
rare IG-related translocations might still pinpoint genes with
unappreciated roles in lymphocyte biology and neoplastic
transformation. Molecular cloning of the breakpoints of a
t(10;14)(q24;q32) chromosomal translocation in a case of B-cell
lymphoma identiﬁed the NKX2-3 gene in chromosome 10q24.2
juxtaposed to the IG heavy-chain (IGH) gene in 14q32.33,
resulting in increased NKX2-3 expression. Further quantitative
PCR studies revealed increased expression of NKX2-3 in a subset
of patients with extranodal and splenic marginal-zone
lymphomas (SMZLs), but not in other B-cell malignancies.
Transgenic expression of human NKX2-3 in mouse B cells
induced the development of lymphomas recapitulating the
principal clinical and biological characteristics of human SMZL.
NKX2-3 aberrant expression resulted in constitutive B-cell
receptor (BCR) signalling, which in turn activated integrins,
adhesion molecules and chemokine receptors that enhanced
migration and promoted homing of B cells to splenic and other
extranodal tissues, eventually driving malignant transformation.
Our study reveals NKX2-3 as a bona ﬁde oncogenic driver in
marginal-zone B-cell lymphomas, and provides an experimental
mouse model to study the functional biology and therapy of this
lymphoma entity.
Results
NKX2-3 expression in marginal-zone B-cell lymphomas.
Molecular cloning by long-distance inverse PCR (LDI-PCR)24 of a
chromosomal translocation t(10;14)(q24;q32) in a patient with
marginal-zone B-cell lymphoma (case 1) mapped the breakpoints
to 3 kb centromeric to the NKX2-3 gene at 10q24.2 and to the 50-
Sg3 region of IGH gene at 14q32.33 (Fig. 1a–c). To ascertain
whether the NKX2-3 gene locus was recurrently targeted by
chromosomal translocations, ﬂuorescence in situ hybridization
(FISH) was used to screen 86 human B-cell lymphoma samples
enriched for chromosome 10q22-26 aberrations based on
cytogenetic data. Notably, FISH analysis of another B-cell
lymphoma carrying a chromosomal translocation t(10;14)
(q24;q11) (case 2) showed the juxtaposition of NKX2-3 to the
gene encoding T-cell receptor alpha (TCRa; Fig. 1d). In both
lymphomas, increased NKX2-3 expression was observed with
respect to non-tumoral B lymphocytes (Fig. 1e). Therefore, NKX2-
3 gene expression is deregulated by chromosomal translocations
involving antigen receptor loci in B-cell lymphoma.
To delineate the pattern of expression of NKX2-3 during
haematopoietic and lymphoid development as well as in
lymphoid neoplasms, quantitative real-time–PCR (qRT–PCR)
was performed in different FACS-sorted human cell populations
and in a collection of B-cell malignancies (Fig. 1f). Although low
levels of NKX2-3 expression were detected in human bone
marrow-isolated CD34þ haematopoietic stem/progenitor cells,
expression of NKX2-3 could not be signiﬁcantly detected in
mature B cells, T lymphocytes or myeloid cells. However, together
with the two cases with chromosomal translocations involving
the NKX2-3 locus, increased NKX2-3 expression was detected in
12 of 393 samples from patients with untreated B-cell lymphoid
malignancies (3%), mainly including 6 of 82 (7%) SMZLs and
4 of 67 (6%) mucosa-associated lymphoid tissue (MALT)
lymphomas. On the other hand, NKX2-3 expression was found
in only 2 out of 244 samples (0.8%) from diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma, mantle cell lym-
phoma, chronic lymphocytic leukaemia or multiple myeloma
(P¼ 0.001; Fisher exact test; Fig. 1f). Immunohistochemistry
(IHC) analysis using a novel rat monoclonal antibody (mAb)
against the full-length GST-fused human NKX2-3 form (286aa,
NM_145285.1) conﬁrmed the previous qRT–PCR data, as human
non-tumoral B, T and myeloid cells appeared negative for
NKX2-3 expression. However, NKX2-3 expression was selectively
detected in the nuclei of splenic CD31þ vWFþCD68CD34þ
aSMA cells (Fig. 1g), corresponding to endothelial cells in the
red pulp sinus25. In addition, IHC analysis showed expression
of NKX2-3 in the nuclei of lymphoma B cells with the
t(10;14)(q24;q32) chromosomal translocation (case 1) as well as
in other marginal-zone lymphoma cases (Fig. 1h). Finally, direct
sequencing of NKX2-3-coding sequence showed no evidence of
pathogenic mutations in lymphoma samples (Supplementary
Table 1). Overall, these data indicate that NKX2-3 is normally not
expressed in mature B lymphocytes, but its aberrant expression is
preferentially observed in a subset of patients with marginal-zone
lymphomas (including SMZL and MALT lymphomas).
Characterization of NKX2-3 deﬁciency in B cells. Consistent
with the expression pattern of NKX2-3 in human lymphoid
subpopulations, murine Nkx2-3 was expressed at low levels in
isolated bone marrow haematopoietic stem/progenitor cells and
in pro-B/pre-B lymphocytes from healthy C57BL/6 mice, but not
in more mature B-cell subpopulations (Fig. 2a). To explore
the potential role of NKX2-3 during B-cell development, the
frequency of different B-cell populations in several lymphoid
organs from 4- and 8-month-old Nkx2-3 / mice was
examined. Flow cytometry analysis did not reveal marked
differences among B- and T-cell subpopulations in the bone
marrow or thymus of Nkx2-3 / and wild-type (WT) animals
(Supplementary Table 2). Therefore, although subtle changes
in other minor subcellular fractions cannot be discarded,
no evidence of NKX2-3 function at the major immature B-cell
stages could be deﬁned. However, a decrease in the total number
of B cells was observed in Nkx2-3 / spleens, including a
complete absence of B220þCD21highCD23low marginal-zone
B cells, whereas the B220þCD21intCD23high follicular B-cell
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compartment was comparable to WT littermates (Fig. 2b).
Furthermore, this dramatic MZ phenotype was accompanied by a
moderate reduction of circulating B220þ IgMþ B cells in
peripheral blood (PB) of Nkx2-3 / mice (Fig. 2b). Together,
these results support the notion that NKX2-3 may affect splenic
marginal-zone organization through regulating homing and
distribution of B cells rather than directly affecting B-cell
development11,13.
NKX2-3 promotes expansion of splenic marginal-zone B cells.
To explore the functional consequences of NKX2-3 expression in
B cells in vivo, C57BL/6-Tg transgenic mice using the EmSRa
enhancer were generated, aiming to drive expression of human
NKX2-3 gene in B lymphocytes, thus mimicking the
t(10;14)(q24;q32) in the index case 1. Two independent founder
mouse lines (L1 and L2) were characterized (Supplementary
Fig. 1a–d). As expected, 2-month-old mice showed restricted
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value for positive NKX2-3 expression was considered when greater than s.d. (standard deviation) x4 of the mean value of the expression of CD19þ cells
plus CD34þ cells. B-CLL, B-cell chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; FCL, follicular lymphoma; MALT, mucosa-associated
lymphoid tissue lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; SMZL, splenic marginal-zone lymphoma. The number of patient samples
analysed in each experiment is shown. (g) IHC analysis of non-tumoral human spleen tissues using moAbs for NKX2-3 (clone 454C/H9), CD34 and
CD68. (h) IHC analysis of different tissues samples from the case with t(10;14)(q24;q32) (case 1). In the left panel, the bone marrow biopsy obtained at
diagnosis shows expression of NKX2-3 in scattered lymphoid B cells. In the middle and right panels, sequential lymph node biopsies obtained during
histological transformation to non-GC DLBCL and subsequent relapse display nuclear expression of NKX2-3 in large B-cell lymphoma cells. Scale
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expression of the NKX2-3 transgene in haematopoietic tissues,
including CD19þ splenic B cells and CD3þ T lymphocytes
(Supplementary Fig. 1e,f). Although L1 mice showed higher
expression of NKX2-3 than L2 mice, and exhibited a more
pronounced phenotype, both lines showed comparable overall
results. In Em-NKX2-3 mice, from about 4 months of age,
a progressive reduction in the number of PB lymphocytes
accompanied by splenomegaly were observed (Fig. 2c,d and
Supplementary Table 3). Sequential ﬂow cytometry studies in
mouse haematopoietic cell compartments at 4, 12 and 18 months
of age did not ﬁnd signiﬁcant changes in the more immature
subpopulations in the bone marrow and thymus (Supplementary
Table 4). However, a gradual decline in the number of circulating
PB mature B220þ IgMþ B lymphocytes and CD4þ and CD8þ
T lymphocytes (including a 3.5-fold decrease in the CD4þ /
CD8þ cell ratio) was observed, which became more evident in
18-month-old mice (Supplementary Table 4). Conversely, the
total number of B lymphocytes increased ten times in transgenic
spleens in comparison with age-matched controls, including a
moderate expansion of B220þCD21highCD23low marginal-zone
B cells and a reduction of B220þCD21intCD23high follicular B
cells (Fig. 2e). Immunoﬂuorescence (IF) analysis of the splenic
tissue architecture in 12-month-old transgenic mice revealed that
IgMþMadCAM-1þ B cells were detectable, initially at the
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T:B-cell boundary and the adjacent region between the follicles
and marginal zone. These transgenic B cells substantially
expanded by 18 months, whereas both the MadCAM-1þ
marginal sinus and its marginal reticular cell support were
destroyed (Fig. 2f). This process was accompanied by a severe
disorganization of the marginal-zone macrophage architecture,
leading to the near-complete loss of MARCO-positive marginal
zone macrophages and a substantial reduction in the number of
sialoadhesin-positive metallophilic macrophages. In addition,
gradual loss of follicular-stromal architecture (evidenced through
fragmentation and collapse of follicular dendritic meshwork) was
detected. However, the segregation of white pulp vasculature and
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red pulp venous sinus network (lost in Nkx2-3 / mice)16
was maintained in Em-NKX2-3 mice (Supplementary Fig. 2).
Therefore, expression of NKX2-3 in lymphocytes led to
lymphopenia in PB and to a progressive splenomegaly with
marginal-zone B-cell expansion, leading to a profound
disorganization of the normal splenic architecture. Notably, this
picture is opposite to the atrophic spleens with the absence of
marginal-zone B cells observed in Nkx2-3 / mice11,13.
El-NKX2-3 mice develop human-like marginal-zone lymphomas.
Aged Em-NKX2-3 mice showed clinical signs of disease and
exhibited shorter survival in comparison to WT animals (median
overall survival for L1 and L2 versus WT mice, 17.5 and 20.4
months versus 25.6 months, respectively; Po0.0001; Fig. 3a).
Upon necropsy, all 38 examined mice (26 from L1, 12 from L2)
showed enlarged spleens, whereas 34 mice (89%) also displayed
extranodal tumours in the small intestine (n¼ 30), the kidneys
(n¼ 22), the liver (n¼ 19), the salivary glands (n¼ 7) and the
lungs (n¼ 6; Supplementary Table 5). Histological analysis of
transgenic spleens revealed a prominent white pulp, composed of
large B-cell inﬁltrates and poorly developed T-cell areas, with an
almost absence of the red pulp. Compartmentalization of the
follicle mantle into a marginal-zone and lymphocytic corona
completely disappeared. The mantle-zone was almost entirely
populated by small B lymphocytes and clusters of these cells
could also be seen in the red pulp, sometimes invading the sinuses
(Fig. 3b). IF and IHC studies detected expression of NKX2-3 in
the nuclei of tumour B220þ B cells, whereas NKX2-3 expression
was not detected in WT mouse lymphocytes (Fig. 3c).
Immunophenotypic characterization showed that B lymphocytes
lacked CD5 expression, and were marked by high surface
expression of IgM and low IgD expression (Fig. 3d). Analysis of
Igh, Igk and Igl gene rearrangements revealed that 18-month-old
splenic B cells harboured clonal rearrangements without IgVh
somatic hypermutation, but this clonality was absent in younger
12-month-old transgenic mice despite signiﬁcant splenomegaly
being present (Fig. 3e). Collectively, these features are consistent
with the diagnosis of human-like SMZL, which in a fraction of
cases show unmutated IGVH gene sequences26,27. In addition,
tumours within extranodal sites were composed of a
heterogeneous population of small and centrocyte-like mature B
cells that inﬁltrated the epithelium and formed lympho-epithelial
lesions, mimicking human MALT lymphomas28,29 (Fig. 3f).
Notably, few splenic and extranodal lymphomas (5 of 32 cases,
16%) showed areas containing large B lymphoblasts with high
proliferation rates, suggestive of histological transformation to
DLBCL, which is a common feature in human marginal-zone
lymphomas, including index Case 1 bearing the t(10;14)(q24;q32)
translocation30,31. These mouse DLBCLs showed expression of
Irf4 and Foxp1, but were negative for Bcl6, CD10 and Gcet1
staining, consistent with a non-germinal centre origin, which is
coincident with the type of DLBCL developed in case 1 (ref. 32;
Fig. 3g). Finally, splenic lymphomas could be propagated in
immunodeﬁcient Rag2 / IL2gc / mice (Supplementary
Fig. 3a), demonstrating the malignant potential of transformed
NKX2-3-positive cells. Collectively, these data show that
Em-NKX2-3 mice generated tumours mirroring the spectrum of
human NKX2-3-expressing B-cell lymphomas.
To determine whether mouse and human lymphomas shared
molecular attributes, gene expression proﬁling was performed in
NKX2-3-expressing mouse splenic lymphomas and compared
with a series of human SMZL samples. Using Linear Models of
Microarray Data Analysis, 42 probe-sets were found differentially
expressed between CD19þ B cells isolated from WT and
12-month-old transgenic spleens, whereas this difference
increased to 630 probe-sets between WT and 18-month-old
splenic B cells (B40; False discovery rate (FDR)o0.27 and
FDRo0.02, respectively; Fig. 3h and Supplementary Data 1).
These data indicate that polyclonal B cells from 12-month-old
transgenic spleens display subtle gene expression differences
compared with normal B lymphocytes, which substantially
increase in the clonal splenic lymphomas in older mice.
Then, gene expression data from resting CD19þ human tonsillar
B cells and human SMZL samples were used to deﬁne a human
SMZL transcriptional signature (B40; FDRo0.03;
Supplementary Data 2), which could then be compared to the
mouse lymphomas. Unsupervised clustering analysis grouped
human SMZL and murine 18-month-old lymphoma samples
together (Supplementary Fig. 3b). Accordingly, the human SMZL
transcriptional signature appeared overrepresented in the murine
18-month-old lymphoma transcriptional datasets, but not in the
12-month-old lymphoma datasets (hypergeometric test,
P¼ 0.0098, and P¼ 0.51, respectively). Likewise, comparison of
the NKX2-3 mouse lymphoma transcriptional signature with two
previously published human SMZL gene expression data sets
revealed a signiﬁcant overlap (P¼ 0.002 and P¼ 0.007; hyper-
geometric test)33,34. Finally, microarray-based high-resolution
comparative genomic hybridization showed genomic
abnormalities in 18-month-old clonal lymphomas (9 of 14,
64%) but not in 12-month-old splenic tumours (n¼ 5). These
changes targeted chromosomal areas syntenic to regions that were
the most frequently rearranged in previous studies of 136 human
SMZL biopsies: trisomies of 3q/12q and losses of 7q/8p (Fig. 3i
and Supplementary Table 6)35,36. Overall, these data show that
Em-NKX2-3 splenic lymphomas and human SMZLs share
signiﬁcant histopathological, immunohistochemical, molecular
and genomic features.
NKX2-3 induces constitutive BCR signalling in young mice.
Virtually all human SMZL and MALT lymphomas show
constitutive BCR activation, which is triggered through
variable mechanisms including microbial antigenic stimulation
Figure 3 | El-NKX2-3 mice develop human-like marginal-zone lymphomas. (a) Kaplan–Meier overall survival curves for the two Em-NKX2-3 transgenic
lines and WTmice. (b) Haematoxilin-eosin (H&E) staining of formalin-ﬁxed parafﬁn-embedded spleen tissues of Em-NKX2-3 transgenic mice. Scale
represents 100mm in all cases. (c) Immunohistochemical (IHC) and immunoﬂuorescence (IF) studies of transgenic spleens using NKX2-3 and B220
antibodies. (d) IHC studies of transgenic spleen biopsies using CD20, IgD, IgM and CD3 antibodies. (e) Detection of Ig gene rearrangements by PCR on
genomic DNA from CD19þ cells isolated from transgenic spleens in 12- and 18-month-old mice. VDJH clonal rearrangements were identiﬁed by direct
sequencing (marked with red arrowheads). Approximate sizes for WT B-cell V(D)J rearrangement bands (labelled 1 to 4) are Jh1: 1800 bp, Jh2: 1200bp,
Jh3: 800 bp and Jh4: 300 bp. B and T, healthy murine B (CD19þ ) and T (CD3þ ) lymphocytes, respectively. (f) H&E staining of extranodal lymphomas
developed in the kidney, the lung and the gut, showing lymphoepithelial lesions. (g) H&E staining of spleen tissue biopsies showing transformation areas
resembling DLBCL. IHC showed positive staining for using CD20, FoxP1 and Mum1 (Irf4), whereas Gcet1, Bcl10 and Bcl6 expression was not observed.
(h) Heat-map image of gene expression proﬁling data showing the 12- and 18-month-old transcriptional signatures in comparison to WT splenic B
lymphocytes. (i) Whole-genome array-based comparative genomic hybridization (aCGH) analysis of isolated CD19þ cells from nine clonal splenic
lymphomas developed in 18-month-old transgenic mice. Chromosomal losses and gains are shown in green and red colours, respectively (bottom).
A representative example is shown (top). m, month.
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or mutations in BCR signalling components27,28,37. These
lymphomas largely depend on BCR signalling for their
survival38. To test whether NKX2-3-induced mouse lymphomas
showed constitutive BCR signalling, B220þ B cells isolated from
transgenic and WT spleens were analysed. In vitro, transgenic B
cells exhibited prolonged cell survival, increased proliferation
(as shown by higher 5-bromodeoxyuridine (BrdU) incorporation
rates), and reduced apoptosis (shown by Annexin/PI staining) in
comparison to WT B cells (Fig. 4a–c). In addition, ﬂow cytometry
analysis revealed an activated cell phenotype (CD44þ , CD69þ ,
CD86þ ), which was increasingly evident in an age-dependent
manner (Fig. 4d). Transgenic B cells showed surface expression
of IgM and IgD, without age-related signiﬁcant changes
(Supplementary Fig. 4a). Investigation of the functional status
of the BCR by western blot analysis revealed phosphorylation of
Lyn (Tyr397) and Syk (Tyr352) tyrosine kinases in NKX2-3-
expressing B cells, indicating constitutive BCR signalling (Fig. 4e).
This abnormal activation was already detected in 6-month-old
mouse B lymphocytes, becoming progressively more evident in
12-month-old tumours and in 18-month-old splenic lymphomas.
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Accordingly, increased and more persistent basal levels of calcium
mobilization were observed in transgenic B cells, either without
stimulation or under anti-IgM stimulation conditions (Fig. 4f).
Moreover, tumour cells exhibited reduced surface expression
of CD22 and of PD-1, and diminished SHP-2 phosphatase
activity in comparison to WT cells (Supplementary Fig. 4b,c).
Importantly, although survival of NKX2-3 transgenic B cells from
younger animals was moderately impaired after incubation with
Lyn and Syk inhibitors, this impairment was signiﬁcantly greater
in 18-month-old clonal B-cell lymphoma cells (IC50 within low
nano-molar ranges; Fig. 4g). These data indicate that NKX2-3-
expressing B cells are prone to exhibit an activated phenotype and
prematurely trigger BCR signalling in young mice even before
developing clinical evidence of disease. Furthermore, constitutive
BCR activation appears increasingly evident with time, and
transgenic B cells become progressively dependent on BCR
signalling for survival.
It is known that constitutive BCR signalling in human SMZL
cells commonly activates downstream NF-kB pathways, and less
frequently alternative MAPK, NFAT and AKT/mTOR path-
ways27,28,39,40. To determine whether similar events occurred in
the NKX2-3-induced splenic lymphomas, investigation of the
status of the BCR downstream signalling cascades was performed.
Western blot analysis revealed phosphorylation of AKT, leading
to PI3K-mTOR activation, but not of other MAP kinases
including JNK and p38 (Fig. 5a). In addition, activation of the
canonical NF-kB cascade (as shown by higher expression levels of
nuclear p50—pointing to an increased processing of p105- and of
c-Rel proteins) but not of the alternative NF-kB pathway was
detected (Fig. 5b,c). Canonical NF-kB signalling increased the
expression of gene components of the NF-kB pathway and
NF-kB target genes (Po0.000001) in the 18-month-old
transcriptional lymphoma data set, and also induced
overexpression of NF-kB target proteins (Fig. 5d,e). Super-shift
assays carried out using antibodies against NF-kB subunits
showed a shift of p50 band in transgenic B cells, thus conﬁrming
the previous ﬁndings (Supplementary Fig. 5a). Of note, although
Lyn and Syk phosphorylation were detected in 6-month-old
transgenic B cells, activation of PI3K-AKT or NF-kB signalling
were detected in 18-month-old clonal lymphoma cells but not in
younger mice, demonstrating them to be late events during
lymphoma development (Supplementary Fig. 5b,c). Overall, these
data suggest that chronic activation of BCR signalling is an early
event in the transformation of NKX2-3-expressing mature B cells,
whereas constitutive activation of downstream PI3K-AKT
and NF-kB pathways appears to be late events potentially
contributing to lymphomagenesis.
NKX2-3 regulates B cells dynamics in lymphoid tissues.
In normal and malignant B cells, BCR signalling regulates
lymphocyte dynamics by modulating their trafﬁc and tissue
location41. Moreover, previous studies of Nkx2-3 / mice here
and elsewhere already pointed towards a critical role of NKX2-3
in the organization of the marginal-zone area and the lymphocyte
homing in the spleen, involving the deregulation of chemokines
and cell adhesion proteins such as MadCAM-1 (refs 11–15). To
test whether this was the case in the Em-NKX2-3 mouse model,
ﬂow cytometry analysis for relevant homing makers was applied
to isolated transgenic and WT CD19þ B cells. Remarkably,
increased expression of multiple cell surface proteins implicated
in homing and cell motility was detected in the tumour cells,
including integrins such as LFA-1 (CD11a), VLA-4 (CD49d) and
MAC-1 (CD11b), and adhesion molecules such as MadCAM-1,
ICAM-1 (CD54) and L-selectin (CD62L). In addition, augmented
expression of the chemokine receptor CXCR4, but not of CXCR5
or CCR7, was detected in transgenic B cells (Fig. 6a and
Supplementary Fig. 6a). Like BCR signalling, these phenotypic
changes occurred gradually, being detected from 12 months of
age and thereafter. However, these were not observed in younger
mice. Functional studies of cell adhesive and motile capacities
revealed that transgenic B cells displayed a signiﬁcant and
progressive increase in migration, either without stimuli or in the
presence of CXCL12 (CXCR4 ligand), CCL21 (CCR7 ligand) and
CXCL13 (CXCR5 ligand) gradients (Fig. 6b). Next, assessment
of integrin activation and cell adhesion showed that, in the
absence of stimuli, lymphoma cells increased their adhesion to
both ICAM-1- and VCAM-1-containing substrates (Fig. 6c,
Supplementary Fig. 6b), indicating basal activation of LFA-1 and
VLA-4 integrins, respectively. Then, using a two-dimensional
model based on artiﬁcial planar lipid bilayers containing
GPI-linked ICAM-1 (ref. 42), B-cell dynamics was analysed in
real time. Although no differences were observed in young mice
(Supplementary Movie 1), a signiﬁcant enhancement in cell
polarization (membrane protrusion activity) and motility was
observed in 12-month-old and older transgenic B cells, which
moved with higher mean velocity values and described longer
tracks than WT B lymphocytes (Fig. 6d,e and Supplementary
Movies 2 and 3). NKX2-3-expressing B cells also moved faster
in response to CXCL12 or CXCL13 chemokines (Fig. 6e,
Supplementary Fig. 6c and Supplementary Movies 4–6). Finally,
transgenic cells adhered more strongly between them in
comparison to WT B lymphocytes, forming large clusters
in vitro (Fig. 6f and Supplementary Movies 3–6). To better
visualize cell cluster formation in vivo, IF analysis of transgenic
spleen sections was performed. A progressive development
Figure 4 | NKX2-3 induces B-cell receptor signalling in B cells from young mice. (a) Cell survival of in vitro cell cultures containing isolated CD19þ cells
from WT and transgenic (TG) mice. Data from three experiments are shown. (b) BrdU staining of WT and TG splenic CD19þ cells isolated after 20 h
of BrdU administration. A representative merged DAPI (blue) and BrdU (red) staining image is shown (bottom). Results of BrdU quantiﬁcation in
WT and TG mice are shown (top). Scale represents 10mm in all cases. (c) Apoptosis quantiﬁcation after 48 h of incubation with etoposide (ETO) or
dimethylsulphoxide (DMSO) in B cells from WT and NKX2-3 TG mice. Data from three experiments are shown. Error bars represent standard deviation
(s.d.). The statistical signiﬁcance levels of the changes are indicated (two-tailed Student’s t-test: *** Po0.0001). (d) Top, Representative ﬂow cytometry
proﬁles (grey ﬁlled histogram) of the indicated molecules at the surface of WT B cells and NKX2-3 TG B cells of the speciﬁed ages (Tg6, 6-month-old mice,
Tg12, 12-month-old mice and Tg18, 18-month-old mice). Dashed black line, maximum expression levels in WT B cells. Dotted histogram, isotype control.
Bottom, quantiﬁcation of the mean ﬂuorescence intensity (MFI) for CD44, CD86 and CD69 surface expression in WTand Tg B cells of the indicated ages;
data are the mean±s.d. (n¼ 3 mice in each case). (e) Western blot analysis showed increased phosphorylation levels of Syk and Lyn kinases in CD19þ
splenic B cells isolated from TG mice at 6, 12 and 18 months. Quantiﬁcation of phosphorylated Lyn and Syk proteins was determined by densitometry,
indicating the ratio respect to the non-phosphorylated form. (f) Kinetics of calcium mobilization in splenic B cells from WTand TG NKX2-3 mice at 12 and
18 months. Top and bottom graphs show the kinetics of non-stimulated and stimulated cells with goat anti-mouse IgM, respectively. Pink arrows indicate
the time points of the stimulation (stim.), whereas green arrows indicate the time points of addition of Ca2þ -containing buffer. (g) Survival of splenic
Em-NKX2-3 CD19þ B-cell lymphoma cell cultures incubated with the Syk and Lyn protein inhibitors (P505-15 and Dasatinib, respectively) at increasing
concentrations. Non-treated cells (NT) were incubated with DMSO. IC50, half maximal inhibitory concentration. Error bars indicates s.d.
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of small-to-medium sized clusters composed of LFA-1- and
ICAM-1-expressing cells intermingled with IgM-producing cells
was documented in 12-month-old tumours, reﬂecting that the
cluster formation was facilitated by adhesion molecules and
integrins that favoured adhesion of B cell among themselves
and with surrounding environmental cells, promoting the
development of large non-clonal tumour masses. Eventually,
in 18-month-old spleens, clonal tumours increased in size and
completely disorganized the splenic architecture (Fig. 6g).
To ascertain whether B cells from patients with SMZL with
expression of NKX2-3 showed similar homing features to those
observed in Em-NKX2-3 murine splenic lymphomas, eight PB
samples from patients with untreated SMZL and from six healthy
donors were analysed. Using qRT–PCR, one of the eight SMZL
samples showed expression of NKX2-3. Interestingly, these P3
lymphoma cells exhibited higher expression levels of LFA-1 and
CXCR4 in comparison to NKX2-3-negative SMZL samples
(Fig. 6h). Furthermore, and consistently with our previous results
in mice (Fig. 6b), B cells from P3 lymphoma also showed an
increased migration index to CXCL12 with respect to the other
samples (Fig. 6i). These results indicate that human SMZL with
expression of NKX2-3 partially recapitulates the features of
NKX2-3-induced lymphomas in mice.
NKX2-3-expressing B cells are sensitive to BCR blockade. Next,
to determine the molecules responsible for the observed changes
in lymphocyte dynamics, transgenic B-cell lymphoma cells were
incubated with different chemical inhibitors. Although no major
differences were observed in cell migration in the absence
of stimuli, in the presence of CXCL12 gradients, migration of
B cells was almost completely abrogated with a selective CXCR4
antagonist (AMD3100), but not with compounds blocking LFA-1
function (A286982; anti-LFA1 antibody; Fig. 7a). Conversely,
adhesion of transgenic B cells to ICAM-1-containing substrates
was markedly reduced by blocking LFA-1 or ICAM-1–LFA-1
interactions, but not upon CXCR4 inhibition (Fig. 7b). Similarly,
cell motility was selectively impaired with ICAM-1/LFA-1
inhibitors but not with the CXCR4 antagonist, while cell
polarization was not affected (Fig. 7c). Then, whether BCR
signalling contributed to the changes in lymphocyte dynamics
was investigated by incubating transgenic B cells with non-lethal
doses of Lyn and Syk chemical inhibitors. A partial reduction in
Lyn/Syk phosphorylation levels was associated with the reversion
of the observed phenotype, including the abrogation of
cell migration in the presence of CXCL12 gradients, adhesion
to ICAM-1 membranes and abnormalities in cell motility
(Fig. 7d–f). Overall, these data show that NKX2-3-induced BCR
signalling increased the expression of multiple surface molecules
in transgenic B cells, including CXCR4 that increased cell
migration, whereas ICAM-1 and LFA-1 enhanced cell adhesion
and motility. These cells abnormally homed to secondary
lymphoid tissues, leading to progressive B-cell accumulation and
eventually driving malignant transformation.
Finally, we used the NKX2-3-induced mouse lymphomas to
evaluate the potential therapeutic efﬁcacy of drugs targeting the
BCR and downstream signalling molecules. Treatment with the
PI3K inhibitor Idelalisib (IC50, 1.5 mM), the BTK inhibitor
Ibrutinib (IC50, 6mM), the MALT1 proteolytic inhibitor MI2
(IC50, 0,56 mM), the NF-kB inhibitor Bay11-7082 (IC50, 13.4 mM)
and two drugs currently used in the treatment of SMZL
(bendamustine and ﬂudarabine) reduced B-cell lymphoma cell
survival, but to a much lesser extent than the chemical inhibitors
of Lyn (Dasatinib, IC50, 33 nM) and Syk (p505-15, IC50, 264 nM)
kinases (Fig. 7g). These data suggest that targeting the BCR with
Lyn and Syk inhibitors may be of therapeutic value in patients
with marginal-zone lymphoma.
Discussion
This study reveals that NKX2-3 is targeted by IG-related
translocations and is abnormally expressed in a subset of patients
with extranodal and SMZLs, but very rarely in other B-cell
malignancies. Although several members of the NKX2 homeobox
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Figure 5 | NKX2-3 induces activation of BCR and downstream signalling pathways in mouse B-cell lymphomas. (a) Western blot analysis showed
increase in AKTphosphorylation levels in splenic CD19þ cells isolated from 18-month-old transgenic (TG) mice in comparison to WTcells, whereas similar
levels of phosphorylation of Jnk (p36/p54) and p38 proteins were detected. (b) Western blot analysis showed similar RelB and p100/p52 expression
in transgenic and WT cells, excluding activation of non-canonical NF-kB pathway. However, expression of p50 and of c-Rel proteins was higher in
18-month-old B-cell lymphoma cells in comparison to WT cells, indicating triggering of the canonical NF-kB pathway. Two representative transgenic and
WT CD19þ splenic B cells are depicted. (c) Western blot analysis of p105 and p50 proteins in cytoplasmic (C) and nuclear (N) extracts from WT and
18-month-old transgenic CD19þ splenic cells. (d) Heat-map image showing gene components of the NF-kB pathway and NF-kB target genes
(http://www.bu.edu/nf-kb/gene-resources/target-genes) differentially expressed between 18-month-old splenic B-cell lymphoma cells and WT splenic
CD19þ B lymphocytes. (e) Western blot analysis of cell cycle proteins in splenic CD19þ cells isolated from WT and transgenic mice.
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family have been involved in the development of solid tumours
and T-cell leukaemias8,21, ectopic expression of NKX2-3 in
mouse B lymphocytes induced the development of clonal
B-cell neoplasms closely mirroring the spectrum of human
NKX2-3-expressing lymphomas. These ﬁndings deﬁne the
homeobox NKX2-3 family protein as a bona ﬁde oncogenic
driver in marginal-zone B-cell lymphomagenesis in human and
mice.
A better understanding of the cellular and molecular
mechanisms underlying the development of marginal-zone
lymphomas will facilitate the diagnosis and treatment of this
heterogeneous disease27,37,43. Currently, there are few diagnostic
and prognostic markers for patients with marginal-zone
lymphomas, and there is not a clear molecular target for these
tumours, particularly for SMZL. In addition, despite the fact that
there are animal models mimicking the principal features of
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human MALT lymphoma44, such models are lacking for SMZL.
We propose that the Em-NKX2-3 mice fully recapitulate the main
cellular, histopathological, molecular and genetic features of
human SMZL, thus representing a valid tool for studying the
functional biology and therapy of this lymphoma entity. The fact
that lymphomas from these Em-NKX2-3mice exhibit activation of
the BCR pathway is particularly interesting, because virtually all
patients with marginal-zone lymphomas show constitutive BCR
signalling, which is triggered by different inﬂammatory and
molecular mechanisms45. However, in a number of cases, the
cause of BCR activation remains elusive. We show that in a small
fraction of tumours, NKX2-3 plays a role in activating BCR
signalling, which may be through a direct effect on Lyn/Syk
tyrosine kinases. However, it is also possible that alternative
indirect mechanisms, for instance antigenic stimulation, are
required during the transformation process. Indeed, we have used
the MD4 BCR transgenic mouse model (in which all B cells
express a BCR speciﬁc for hen egg lysozyme) to evaluate the
putative role of BCR activation by autoantigens in the tumour
development process. Analysis of three NKX2-3 transgenic mice
MD4 negative (polyclonal BCR repertoire) and three transgenic
mice NKX2-3 MD4 positive (monoclonal BCR repertoire) at
6 months of age showed lower levels of activated Syk in the latter
group in comparison to the MD4-negative mice. These data
suggest that antigen stimulation of the BCR may have a
role in the lymphomagenesis observed in our mouse model
(Supplementary Fig. 4d).
Em-NKX2-3 mice exhibited a sequential model of lymphoma
development. Constitutive BCR signalling was observed from
6 month of age, which was followed by signiﬁcant molecular and
cellular dynamic changes in B cells that facilitated their homing to
spleen tissues, whereby they became adherent and were retained
by stromal cells to accumulate and progressively develop
non-clonal tumours. At B18 months, B cells acquired genomic
rearrangements that activated NF-kB and PI3K-AKT signalling
pathways, which promoted cell proliferation and survival,
progressively inducing the formation of clonal B-cell lymphomas.
Although constitutive activation of BCR and downstream
signalling pathways has been implicated in human marginal-
zone lymphoma development34,39,40, abnormal migration,
homing and adhesion as mechanisms involved in the
pathogenesis of these tumours represent novel ﬁndings that
warrant further investigation. Intriguingly, many patients with
SMZL are preceded by an asymptomatic low-count B-cell
lymphocytosis that progressively increases in number and in
some cases associates with splenomegaly, eventually fulﬁlling
the diagnostic criteria of SMZL46. Accordingly, this observation
suggests that human SMZL and NKX2-3-induced mouse
lymphomas may follow a similar sequential model of tumour
development. Although our model recapitulates many aspects of
human marginal-zone lymphoma biology, we think it has
limitations that include the long tumour latency (which on the
other hand reﬂects the slow development of SMZL observed in
patients), and the fact that tumours are triggered by the activation
of NKX2-3 in B cells, which is only observed in a fraction of
patients with MALT lymphoma and SMZL.
In summary, our study reveals that oncogenic NKX2-3
promotes B-cell lymphomagenesis by activating BCR signalling
and disturbing lymphocyte dynamics, and provides an
experimental mouse model that recapitulates the major features
of human SMZL. Finally, our data suggest that targeting the BCR
with inhibitors of Lyn and Syk kinases may be of therapeutic
value in patients with marginal-zone lymphomas.
Methods
Human primary samples. A patient diagnosed of marginal-zone lymphoma
showed an abnormal karyotype in 4 out of 16 examined bone marrow cells:
46,XY,del(7)(q32q36),t(10;14)(q24;q32). DNA isolated from these cells was used
to clone the t(10;14)(q24;q32) by LDI-PCR24. In addition, four-hundred eighty
samples obtained from untreated patients with mature B-cell malignancies,
collected from different institutions participating in the study, were analysed. The
study was performed in the accordance with the regulations of the Institutional
Review Board of the University of Navarra, and was conducted according to the
Declaration of Helsinki principles. Informed consent was obtained from all
patients.
Long-distance inverse PCR. LDI-PCR was performed to screen for
rearrangements involving the IGHJ segments in the lymphoma cells carrying
the t(10;14)(q24;q32). Brieﬂy, high-molecular-weight DNA was digested with
restriction enzymes chosen from the results of DNA blot to yield small DNA IGHJ
fragments. Phenol/chloroform extraction was performed to remove residual
enzymatic activity, and 0.4 mg of digested DNA was then ligated at 15 C overnight
in a total volume of 500 ml with 5U of T4 DNA ligase (Promega). The ligated DNA
was then puriﬁed using the Wizard DNA clean-up system (Promega) and eluted in
a ﬁnal volume of 40ml. Primers were designed within the JH and IGH enhancer
regions based on published sequences (Supplementary Table 7), so that the
ampliﬁcation products would include short stretches from these regions in addition
to the rearranged or translocated regions 50 of JH. In addition, restriction sites to
permit forced cloning into plasmid vectors were introduced24.
Quantitative real-time PCR. Total RNA was isolated from harvested cells and
patient samples using TRIzol (Invitrogen). RNA was converted into cDNA using
random hexanucleotides and the M-MLV reverse transcriptase (Invitrogen).
In human samples, NKX2-3 expression was measured using a TaqMan probe
(Hs00414553_g1, Applied Biosystems) normalized to GAPDH (Hs99999905_m1,
Applied Biosystems). In mouse samples, Nkx2-3 gene expression quantiﬁcation
was performed using the SYBR Green PCR Master Mix (Applied Biosystems)
normalized to mouse Gapdh. Quantitative real-time–PCR was performed in
the 7300 Real-Time PCR System with universal PCR Master Mix (Applied
Biosystems). For each sample, a DCt value was calculated as the threshold
cycle (Ct) value of the NKX2-3/Nkx2-3 gene (target) minus the Ct value of
GAPDH/Gapdh (control). A cutoff value for considering a sample positive for
NKX2-3 expression was calculated as four-times the standard deviation (s.d.) of the
Figure 6 | Phenotypic analysis and characterization of cell dynamics in NKX2-3-expressing B cells. (a) Representative ﬂow cytometry proﬁles
(grey ﬁlled histogram) of forward side scatter (FSC) and the indicated molecules at the surface of WT B cells and NKX2-3 transgenic (Tg) B cells of the
speciﬁed ages (Tg6, 6-month-old mice, Tg12, 12-month-old mice and Tg18, 18-month-old mice). Dashed black line, maximum expression levels in WT B
cells. Dotted histogram, isotype control. (b) Migration frequencies of WTand transgenic B cells of the indicated ages in Boyden chambers in the absence or
presence of CXCL12, CXCL13 or CCL21. Data are the mean±s.d. (n¼4). Error bars represent standard deviation (s.d.) in all cases. (c) Frequency of
adhesion to ICAM-1 (top) or VCAM-1 (bottom) containing artiﬁcial membranes of WT and transgenic B cells. Data are the mean±s.d. (n¼ 2).
(d) Cell polarization frequencies, indicating the fractions of non-motile and motile cells, of WTand transgenic B cells settled on ICAM-1-membranes in the
absence (top) or presence of CXCL12 chemokine (bottom); data are the mean±s.d. (n¼ 2). (e) Mean velocity values of motile WTand transgenic B cells;
data are derived from two experiments and each dot is a single cell. (f) Representative wide-ﬁeld images of WT B cells (top) and transgenic B cells
(bottom) after 24 h of culture. (g) IF analysis of WT and transgenic spleens from 12- and 18-month-old mice: (left) Clustering of B cells in LFA-1þ
compartments in ageing Em-NKX2-3 mice: in WTmice (top) LFA-1þ (green) cells are restricted to the red pulp (arrow), whereas the follicles stained with
anti-IgM (red; Fo) are devoid of such cells. Scale bar, 200mm. (h) Representative ﬂow cytometry proﬁles (ﬁlled histogram) of the indicated molecules at the
surface of human B cells from healthy donors (HD) and patients (P3, patient positive for NKX2-3 expression; P4, P5, P6, patients negative for NKX2-3
expression). Dotted histogram, isotype control in each case. (i) Migration index of human B cells from healthy donors (n¼4), P3 (patient positive for
NKX2-3) and patients negative for NKX2-3 expression (n¼ 7) in response to gradients of CXCL12.
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Figure 7 | Functional characterization of cell dynamic changes in El-NKX2-3 transgenic mice. (a) Migration frequencies of transgenic B cells non-treated
(none) or treated with the indicated chemical inhibitors (AMD, CXCR4 antagonist, 10mM; A286, LFA-1–ICAM-1 interaction inhibitor, 10mM; anti-LFA1,
blocking antibody anti-mouse CD11a, 1 mgml 1) in Boyden chambers in the absence (none-chemokine) or presence of CXCL12 (10 nM). Signiﬁcance levels
of changes are indicated (two-tailed Student’s t-test: *Po0.05, **Po0.001, ***Po0.0001) in all a–f cases. (b) Frequency of adhesion to ICAM-1-
containing artiﬁcial membranes of transgenic B cells none-treated or treated with the indicated chemical inhibitors. (c) Cell polarization frequencies,
indicating the fractions of non-motile and motile cells, of transgenic B cells none-treated or treated with the indicated chemical inhibitors and settled on
ICAM-1-membranes in the absence of CXCL12 chemokine. Data in a,b,c are the mean±s.d. (n¼4). (d) As in a using the chemical inhibitors Dasatinib
(Das, 1mM; Lyn inhibitor) and P505-15 (P505, 1 mM; Syk inhibitor). (e) As in b using the indicated inhibitors. (f) As in c using the indicated inhibitors. Data
in d,e,f are the mean±s.d. (n¼ 3). (g) Survival of splenic Em-NKX2-3 CD19þ B-cell lymphoma cell cultures incubated during 24 h with the BTK inhibitor
(Ibrutinib), the PI3K inhibitor (Idelalisib), the MALT1 proteolytic inhibitor (MI2), the NF-kB inhibitor (Bay11-7082), bendamustine and ﬂudarabine at
increasing concentrations. Non-treated cells (NT) were incubated with dimethylsulphoxide (DMSO). IC50, half maximal inhibitory concentration. Error bars
indicates s.d.
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2DCt value of NKX2-3 expression in the human CD19þ and CD34þ cell
samples. The primers used are listed in Supplementary Table 7.
Fluorescence in situ hybridization. FISH was applied to screen for chromosomal
breakpoints involving the NKX2-3 gene locus (chr10: chr10:101,292,690-
101,296,280, hg19) using a break-apart assay consisting of two differently labelled
BAC clones CTD-3188C19 (chr10:101075221-101281059, hg19) and RP11-157O7
(chr10:101308986-101475976 hg19)47, following previously reported methods48.
Screening for NKX2-3 gene abnormalities was performed on ﬁxed cells left over
from routine cytogenetic studies of 86 mature B-cell leukaemias and lymphomas,
including 37 cases with chromosomal changes affecting bands 10q22-q26, 39 cases
with other cytogenetic abnormalities, and 10 cases with a normal karyotype.
The NKX2-3-TCRA/D fusion was investigated using a triple colour assay, which
included the NKX2-3 probes described above labelled in spectrum aqua and
the commercial LSI TRA/D Dual Color Break apart Rearrangement Probe
(Abbott/Vysis).
Generation of NKX2-3 mAb. A human NKX2-3 cDNA clone encoding full-length
NKX2-3 protein was used to bacterially express a GST fusion protein for
immunization in two Wistar rats, using previously reported methods49. The
hybridoma fusion generated seven mAbs, two of which were selected because they
selectively reacted with NKX2-3 and not with other NKX2 family proteins by
ELISA. Both showed a similar nuclear staining pattern in splenic endothelial cells
by IHC, but did not work for western blot analysis. The NKX2-3 5GAL-454C/H9
clone was selected for further studies.
IHC and western blot analyses. Parafﬁn-embedded mouse and human
lymphoma tissues included in the study were centrally reviewed by at least two
expert haemopathologists (listed as authors in this study), and diagnosed according
to the World Health Organization criteria29. For comparative studies, age-matched
WT mice were used. For western blot analysis, equal amounts of total protein
(10–50 mg) were separated on SDS–polyacrylamide gel electrophoresis, and
electrotransferred onto nitrocellulose membranes. Membranes were incubated with
primary antibodies, followed by secondary antibodies conjugated to horseradish
peroxidase, which were detected by chemiluminescence (Applied Biosystems and
Pierce, respectively)50. IHC and western blot antibodies are listed in Supplementary
Table 8. In the ﬁgures, molecular-weight size markers in kDa are shown. When
indicated, the quantiﬁcations of bands from western blot was performed by
densitometry, and subsequent analysis using Quantity One software (Bio-Rad).
Generation and characterization of NKX2-3-deﬁcient mice and El-NKX2-3
transgenic mice. Knock-out mice for Nkx2.3 gene have been previously
reported11. Human NKX2-3 cDNA was cloned into the HindIII SacI of the pEmSR
vector (kindly provided by Jerry Adams), to obtain the pEmSR-NKX2-3 vector.
A 4.455-bp PciI AatII fragment containing the NKX2-3 gene was isolated from the
pEmSR-NKX2-3 vector, puriﬁed and injected into fertilized oocytes of C57BL/6
mice background. Mice were crossed onto C57BL/6 genetic background and
housed in the speciﬁc pathogen-free animal facilities of our centre. All the
experiments were conducted with protocols approved by the Ethical Committee of
Animal Experimentation of the University of Navarra. Mice were characterized
for transgene integration by PCR and Southern blot (Supplementary Fig. 1c,d).
The PCR was designed to detect the transgene random integration event. The
transgene-containing mice showed a PCR product of 586 bp. (Supplementary
Fig. 1c). Mice positive by PCR for the presence of the transgene were veriﬁed by
Southern blot analysis using a 473-bp. JMC-1 probe designed by PCR ampliﬁcation
from the pEmSR-NKX2-3 vector. The hybridization signal of JMC-1 probe
indicated the presence of the SacI fragment in the sample, containing the transgene.
Supplementary Fig.1d shows the results of the Southern blot analysis performed in
eight animals, allowing the selection of the founder mice used in this study. Primers
for the genotyping PCR and the probe construction are listed in Supplementary
Table 7. NKX2-3 transgenic females were crossed with MD4 BCR transgenic males
(kindly provided by Dr Yolanda R. Carrasco), both in C57BL/6 background and
of similar ages (2–3 months old). The F1 generation was genotyped, and born
NKX2-3 transgenic MD4-positive mice in comparison to born NKX2-3 transgenic
MD4-negative mice were monitored for B-cell activation and/or transformation.
Mouse blood cell count. PB samples were collected from transgenic and
WT mice. The following parameters were measured using 40 ml of PB with a
HEMAVET HV950FS multispecies hematology instrument (Drew Scientiﬁc, Inc.):
white blood cells, lymphocytes, neutrophils, monocytes, eosinophils, basophils,
red blood cells and haemoglobin.
Measurement of spleen size using ultrasounds. Ultrasound examination of the
spleen size was performed in WT and transgenic mice at 4, 12 and 18 months. For
each age group, at least eight mice were analysed. The sagital and longitudinal
spleen lengths were measured by micro-ultrasound imaging using the Vevo770
high-resolution in vivo micro imaging system (VisualSonics), and data were
analysed using the Vevo770 v.3.0 software.
Flow cytometry analyses. BM, PB, spleen, thymus and lymph node nucleated
cells were extracted from Nkx2-3 / , Em-NKX2-3 and matched healthy C57BL/6
mice. Preparation of the cells for ﬂow cytometry and staining studies was
performed according to the standard procedures44,50. Cells were acquired in a
cytometer FACScalibur (BD Biosciences), and further analysed using the FlowJo
7.6.3 software. Monoclonal antibodies were obtained from BD Biosciences, except
for anti-MadCAM-1 antibody (Santacruz Biotechnology), for anti-mouse CCR7
antibody, anti-mouse CD22 and anti-mouse CD279 (PD-1; BioLegend), and for
anti-mouse IgM (Jackson ImmunoResearch), and are listed in Supplementary
Table 9.
Cell isolation. Cell sorting of different subpopulations in C57BL/6 mice was
performed using a FACSAria (BD Biosciences), as reported44. The haematopoietic
stem/progenitor cell isolation was performed by incubating BM cells with anti-Sca1
and anti-lineage marker antibodies (CD4, CD8, B220, Gr1 and Mac1) to obtain
Sca1þLin cells. The remaining BM cell subpopulations were marked as follows:
pro-B cells, B220lowc-Kitþ ; pre-B cells, B220lowCD25þ ; recirculating B cells,
B220highIgMþ and immature B cells, B220lowIgMþ . Splenic cell subpopulations
were marked as follows: mature B cells, B220þ IgDhighIgMlow, immature B cells,
B220þ IgDlowIgMhigh, follicular B cells, B220þCD23þCD21low and marginal-
zone B cells, B220þCD23CD21high. Isolation of splenic CD19þ and CD3þ cells
from WT and transgenic mice were carried out using the AutoMACs separation
system with CD19 or CD3 microbeads (Miltenyi-Biotec), respectively. Isolated cell
subpopulations were reanalysed for purity by ﬂow cytometry (purity 498%). For
chemotaxis and cell dynamics assays, primary B cells from spleens of WT and
NKX2-3 transgenic mice were isolated by negative selection (495% purity) using
pan-T (Thy1.2) dynabeads (DYNAL), as described42. Age-matched WT and
NKX2-3 transgenic mice were used on each experiment. Human B cells were
obtained from PB of healthy donors (buffy coats samples kindly supplied by the
Centro de Transfusiones Comunidad de Madrid) and patients by negative selection
(495% purity) using Dynabeads Untouched Human B cells kit (DYNAL) after a
Ficoll-gradient centrifugation step.
Cell survival and proliferation. Spontaneous cell survival was determined by
incubating isolated WT and transgenic splenic CD19þ B cells at a density of
2.5 106 cells per ml during 48 h. Cell viability was assessed by trypan-blue dye
exclusion. Apoptosis was measured by Annexin V/propidium iodide staining after
treatment with etoposide at 10 mM during 48 h. For BrdU staining, cells were ﬁxed
with 4% paraformaldehyde, washed with PBS and incubated in 1N and 2N HCl,
10min each, at 37 C. After PBS washing, cells were treated 12min with 0.1M
Borate Buffer, and incubated overnight with BrdU mAb following incubation with
secondary anti-rat antibody.
V(D)J Recombination analysis of mouse B-cell tumours. Ig gene rearrange-
ments were ampliﬁed by PCR using primers speciﬁc for several V gene families in
conjunction with reverse J primers51. PCR bands were cloned into a plasmid
vector, and eight to ten clones from each puriﬁed band were sequenced and
analysed for the presence of somatic hypermutation of Ig gene sequences.
Gene expression microarray data analysis. Samples were processed according to
reported methods44,50. The cDNAs were hybridized to the Affymetrix HG-U133
Plus2 arrays in the case of human samples. Mouse samples were similarly
processed and hybridized to the Affymetrix GeneChip Mouse Gene 1.0 ST arrays.
Raw gene expression microarray data ﬁles were submitted to GEO and are available
under the accession number GSE49356. Both background correction and
normalization were done using RMA (Robust Multichip Average) algorithm.
Then, a ﬁltering process was performed to eliminate low-expression probe sets.
R/Bioconductor was used for preprocessing and statistical analysis. Linear Models
for Microarray Data were used to ﬁnd out the probe sets that showed signiﬁcant
differential expression between experimental conditions. Genes were selected as
signiﬁcant using a B statistic cutoff B40.
Functional and pathway analysis of gene expression signatures. These
analyses were performed according to standard procedures44,50. Brieﬂy, functional
enrichment analysis of Gene Ontology categories was carried out using standard
hypergeometric test. The biological knowledge extraction was complemented
through the use of Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com), which database includes manually curated and fully traceable
data derived from literature sources. To study the biological meaning of the results,
enrichment tests with respect to MsigDB gene sets was carried out. To this end, the
non-parametric Kolmogorov–Smirnoff rank test was used as implemented in the
Gene Set Enrichment Analysis software. Owing to the stochastic nature of this
procedure, the test was performed ﬁve times and the P-values for each gene-set
were computed based on 5,000 permutation iterations. The FDR was calculated for
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multiple hypothesis testing correction. A hypergeometric test was used to calculate
the signiﬁcance of the overlap between the NKX2-3 signatures and previously
published human SMZL transcriptional data set33,34.
High-resolution comparative genomic hybridization (aCGH) to microarray.
Genomic DNA was extracted from CD19þ cells isolated from transgenic (n¼ 19)
and WT spleens (n¼ 2, used as normal hybridization controls). Whole-genome
analysis was conducted using a 180-K oligonucleotide mouse aCGH microchip
(AMADID 27411, Agilent Technologies), following standard protocols52.
Microarray data were extracted and visualized using Feature Extraction v10.7 and
Agilent Genomic Workbench v5.0 softwares (Agilent Technologies). Regions with
DNA copy number abnormalities were detected using ADM-2 (seta s 6) statistic
provided by DNA Analytics, with a minimum number of 5 consecutive probes.
Genomic build mm7 was used for the experiment. For comparison of the murine
lymphoma genomic changes with those present in human disease, two previously
published studies including the aCGH analysis of 136 samples from patients with
SMZL were used35,36.
Chemotaxis assays. Puriﬁed B cells (3 105) resuspended in 100ml RPMI 10%
FCS were added to the upper insert of Boyden chambers (Costar). Then, the upper
insert was placed in the lower chamber that contains 600 ml RPMI 10% FCS alone
or in the presence of chemokine (recombinant human CXCL12 and recombinant
murine CXCL12, CXCL13, or CCL21; Preprotech) at the speciﬁed concentration.
Cells were incubated at 37 C for 2 h 30min, collected from the lower chamber, and
counted for 1min at high ﬂow rate in a FACScalibur cytometer (BD Bioscience).
We use Boyden chambers of 3 mm (mouse B cells) or 5 mm (human B cells) pore
size; each assay was done per duplicate. Migration frequency was calculated as the
percentage of cells from the input that migrate to the lower chamber ((no. of cells
at lower chamber/no. of cells at the input) 100); the input cell number was
obtained placing 100 ml of the initial cell suspension in 500 ml PBS and counting
them as explained. In the assays with human B cells, Migration Index was
calculated as the ratio between the no. of cells at the lower chamber in each
chemokine condition and the no. of cells at the lower chamber in the absence of
chemokine (basal migration) for each sample (healthy donor or patient).
Calcium mobilization assay. Splenic cells (107) from WT and transgenic
Em-NKX2-3 mice were stained with anti-CD19. Cells were twice washed with
RPMI-1640 medium and stained with 2 mM of Fluo-4 AM (Invitrogen) for 30min.
Cells were collected and resuspended in 1ml of RINGEN buffer (155mM NaCl;
4.5mM KCl; 3mM MgCl2; 10mM D-Glucose; 5mM HEPES). When indicated,
cells were stimulated with 10 mgml 1 anti-IgM, and later, the buffer was
supplemented with 2mM of CaCl2. Intracellular Ca2þ mobilization was measured
in real-time by FACScalibur (BD Biosciences) with a laser tuned at 488 nm.
Raw data ﬁles were analysed using FlowJo 7.6.4 software.
Adhesion assays and time-lapse microscopy on planar lipid bilayers. Artiﬁcial
planar lipid bilayers containing GPI-linked mouse ICAM-1 or VCAM-1 (density
150molecules per mm2) were prepared and used in the study42,53. Brieﬂy,
membranes were assembled on FCS2 chambers (Bioptechs), blocked with PBS/2%
FCS (1 h, room temperature (RT)) and when indicated, coated with 100 nM
chemokine immediately before use (30min, RT). Puriﬁed NKX2-3 transgenic and
WT B cells were ﬂuorescently labelled with CFSE or SNARF-1 probes (0.1 mM,
10min, 37 C; Molecular Probes), mixed at 1:1 ratio, injected into the warmed
chamber (4 106, 37 C), allowed to settle on the membranes (5–10min), and
imaging was initiated. Confocal ﬂuorescence, differential interference contrast and
interference reﬂection microscopy (IRM) images were acquired every 8 s for 15min
to evaluate cell dynamics; two or three consecutive videos were acquired in distinct
membrane positions per chamber. For cell adhesion measurements, snapshots in
different membrane positions were acquired. Assays were performed in PBS/0.5%
FCS/0.5 g l 1 D-glucose/2mM MgCl2/0.5mM CaCl2. Images were acquired on an
Axiovert LSM 510-META inverted microscope with a  40 oil immersion
objective (Zeiss). Imaging analysis of cell adhesion and dynamic parameters
were done using Imaris 7.0 software (Bitplane) and ImageJ software (NIH).
Adhesion frequency was calculated as (no. of cells in contact with the ICAM-1- or
VCAM-1-containing membrane (IRMþ )/total no. cells in the ﬁeld) 100; we
calculated polarization and motility frequencies similarly. Assays were performed
using NKX2-3 transgenic and WT B cells isolated from mice of same age, and
comparing data between them. Similar data were obtained with WT B cells
independently of the mouse age.
IF studies. Frozen and acetone-ﬁxed sections were blocked with 5% BSA in PBS
for 20min. Triple label ﬂuorescence for marginal reticular cells, marginal sinus and
B cells was performed using FITC-conjugated rat mAb IBL-11 in a cocktail
with Cy3-labelled anti-MAdCAM-1 mAb (clone MECA-367) and Alexa Fluor
647-labelled anti-rat IgM (clone B7.6). Three-colour staining for marginal zone
macrophages was performed with incubating the sections ﬁrst with anti-
sialoadhesin mAb MOMA-1 (AbD Serotec) in conjunction with FITC-labelled
sheep anti-rat IgG (BD Biosciences), where residual binding sites of secondary
antibody were blocked with 5% normal rat serum. Subsequently, a cocktail of
Cy-labelled anti-rat MARCO (clone IBL-12) and Alexa Fluor-647-labelled anti-
IgM was added. Follicular dendritic cells and marginal sinus were identiﬁed using a
cocktail of FITC-conjugated anti-CD21/35 mAb (clone 7G6 from BD Biosciences)
and Cy3-labelled anti-MAdCAM-1 mAb. Staining for VCAM-1 and ICAM-1
expressed by B cells was performed by incubating sections ﬁrst with unlabelled
rat mAbs (anti-VCAM-1 clone 429 from BD Biosciences or anti-ICAM-1 clone
YN1/1, kindly provided by Dr Andras K. Szakal) followed by FITC-labelled sheep
anti-rat IgG (BD Biosciences) and saturation with 5% normal rat serum. Rat
anti-mouse LFA-1 antibody (clone M17/4 from American Type Culture Collection)
was used as hybridoma supernatant. B cells were identiﬁed using Alexa Fluor
647-labelled anti-rat IgM, for 45min incubation each at room temperature in a
humid chamber. Triple staining for red pulp vessels, marginal sinus and white
pulp vasculature was accomplished using a cocktail of FITC-conjugated rat
mAb IBL-7/1 against marginal sinus and white pulp vessels, Cy3-conjugated
anti-MAdCAM-1 mAb and Alexa Fluor647-labelled IBL-9/2 mAb against red pulp
sinuses. After mounting, the sections were viewed under an Olympus BX61
ﬂuorescent microscope. The acquisition of digital pictures with a CCD camera was
performed using the analySIS software. IF antibodies are listed in Supplementary
Table 8.
Chemical inhibitors. For therapeutic experiments, mouse transgenic B-cell
lymphoma cells were incubated at 2.5 106 cells per ml for 24 h with the following
compounds at increasing concentrations: PI3K inhibitor (Idelalisib; Chemie Tek);
BTK inhibitor (Ibrutinib; Chemie Tek); MALT1 proteolytic inhibitor (MI2); NF-kB
inhibitor (Bay11-7082; Enzo LifeSciences); Lyn inhibitor (Dasatinib; Selleckchem);
Syk inhibitor (P505-15; Selleckchem). For chemotactic and cell dynamics assays,
mouse B cells were incubated at 3 106 cells per ml for 1 h at 37 C with the
following compounds: CXCR4 antagonist (AMD3100; 10 mm); blocking rat
anti-mouse LFA-1 (CD11a) antibody (clon M17/4; 1 mgml 1; BioLegend);
LFA-1–ICAM-1 interaction inhibitor (A286982; 10 mm); Lyn inhibitor (Dasatinib;
1 mm) and Syk inhibitor (P505-15; 1 mm). Then, they were used in the assays
keeping the presence of the chemical inhibitor.
Electrophoretic mobility gel shift array. Cells were lysed and nuclear fractions
were resuspended in 20mM HEPES, pH 7.9, 420mM NaCl, 1mM EDTA, 1mM
ethyleneglycol tetraacetic acid and 20% glycerol. Nuclear extracts (10mg of
total protein) were incubated with a 32p-labelled double-stranded DNA probe
corresponding to the consensus NF-kB site (50 -GGGAATTTCC-30). Samples were
run on a 5% non-denaturing polyacrylamide gel in 200mM Tris-borate, 2mM
EDTA. Gels were dried and visualized by autoradiography. Supershifts were
performed using rabbit polyclonal antibodies speciﬁc for p50, p65, c-Rel, p52,
RelB or irrelevant anti-GATA1 antibodies (all from Santa Cruz Biotechnology).
Statistical analysis. Overall survival in transgenic mice was deﬁned as the time
interval between the date of birth and the date of death. Survival curves were
estimated using the product limit method of Kaplan–Meier and were compared
using the log-rank test. Two-tailed t-tests (normally distributed data) or
Mann–Whitney U-test (non-normally distributed data) were used for evaluating
the signiﬁcance of differences at gene expression of WT versus transgenic samples,
as appropriate. Statistical analyses were carried out using GraphPad Prism 5.0
software (GraphPad). In the case of chemotaxis, cell adhesion and other cell
dynamics parameters, statistical analysis and graphs were done using GraphPad
Prism 4.0 software. Two-tailed unpaired Student’s t-test was applied to compare
each NKX2-3 transgenic B cells population with its control (WT B cells); *Po0.05,
**Po0.001, ***Po0.0001.
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